<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30259416</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>27</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2211-3436</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>Cellular oncology (Dordrecht)</Title>                <ISOAbbreviation>Cell Oncol (Dordr)</ISOAbbreviation>            </Journal>            <ArticleTitle>Emerging ways to treat breast cancer: will promises be met?</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13402-018-0409-1</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast cancer (BC) is the most common cancer among women and it is responsible for more than 40,000 deaths in the United States and more than 500,000 deaths worldwide each year. In previous decades, the development of improved screening, diagnosis and treatment methods has led to decreases in BC mortality rates. More recently, novel targeted therapeutic options, such as the use of monoclonal antibodies and small molecule inhibitors that target specific cancer cell-related components, have been developed. These components include ErbB family members (HER1, HER2, HER3 and HER4), Ras/MAPK pathway components (Ras, Raf, MEK and ERK), VEGF family members (VEGFA, VEGFB, VEGFC, VEGF and PGF), apoptosis and cell cycle regulators (BAK, BAX, BCL-2, BCL-X, MCL-1 and BCL-W, p53 and PI3K/Akt/mTOR pathway components) and DNA repair pathway components such as BRCA1. In addition, long noncoding RNA inhibitor-, microRNA inhibitor/mimic- and immunotherapy-based approaches are being developed for the treatment of BC. Finally, a novel powerful technique called CRISPR-Cas9-based gene editing is emerging as a precise tool for the targeted treatment of cancer, including BC.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Potential new strategies that are designed to specifically target BC are presented. Several clinical trials using these strategies are already in progress and have shown promising results, but inherent limitations such as off-target effects and low delivery efficiencies still have to be resolved. By improving the clinical efficacy of current therapies and exploring new ones, it is anticipated that novel ways to overcome BC may become attainable.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Samadi</LastName>                    <ForeName>Pouria</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Saki</LastName>                    <ForeName>Sahar</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dermani</LastName>                    <ForeName>Fatemeh Karimi</ForeName>                    <Initials>FK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pourjafar</LastName>                    <ForeName>Mona</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Saidijam</LastName>                    <ForeName>Massoud</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. sjam110@yahoo.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Cell Oncol (Dordr)</MedlineTA>            <NlmUniqueID>101552938</NlmUniqueID>            <ISSNLinking>2211-3428</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">CRISPR-Cas9 editing</Keyword>            <Keyword MajorTopicYN="N">Cancer vaccines</Keyword>            <Keyword MajorTopicYN="N">Immunotherapy</Keyword>            <Keyword MajorTopicYN="N">Long noncoding RNAs</Keyword>            <Keyword MajorTopicYN="N">MicroRNAs</Keyword>            <Keyword MajorTopicYN="N">Small molecule inhibitors</Keyword>            <Keyword MajorTopicYN="N">Targeted therapy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30259416</ArticleId>            <ArticleId IdType="doi">10.1007/s13402-018-0409-1</ArticleId>            <ArticleId IdType="pii">10.1007/s13402-018-0409-1</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>